174 related articles for article (PubMed ID: 28315807)
1. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
[TBL] [Abstract][Full Text] [Related]
2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
Yoon HY; Ahn MH; Yee J; Lee N; Han JM; Gwak HS
Eur J Clin Pharmacol; 2020 Aug; 76(8):1053-1058. PubMed ID: 32385545
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Zhu X; Li X; Zhang T; Zhao L
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
[TBL] [Abstract][Full Text] [Related]
5. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
7. Association of valproic acid and 2-propyl-4-pentenoic acid concentrations with adverse reaction in 254 Chinese patients with epilepsy.
Ma H; Zhu W; Wang C; Pan J; Yang X; Luo J; Wang P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Jul; 44(7):775-783. PubMed ID: 31413215
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
9. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y; Yu J; Yuan Q; Wu X; Wu X; Hu J
Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):85. PubMed ID: 28841884
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
[TBL] [Abstract][Full Text] [Related]
11. Effects of
Zheng XX; You YX; Zhao LL; Du Y; Xu SQ; Tang DQ
Pharmacogenomics; 2023 Feb; 24(3):153-162. PubMed ID: 36718958
[No Abstract] [Full Text] [Related]
12. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
Guo Y; Hu C; He X; Qiu F; Zhao L
Drug Metab Pharmacokinet; 2012; 27(5):536-42. PubMed ID: 23099353
[TBL] [Abstract][Full Text] [Related]
13. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A
Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
[TBL] [Abstract][Full Text] [Related]
15. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
[TBL] [Abstract][Full Text] [Related]
16. Catalase C-262T Polymorphism Is a Risk Factor for Valproic Acid-Induced Abnormal Liver Function in Chinese Patients With Epilepsy.
Ma L; Pan Y; Sun M; Shen H; Zhao L; Guo Y
Ther Drug Monit; 2019 Feb; 41(1):91-96. PubMed ID: 30422963
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
Numa AM; Abbott FS; Chang TK
Can J Physiol Pharmacol; 2007 Sep; 85(9):848-55. PubMed ID: 18066130
[TBL] [Abstract][Full Text] [Related]
19. Impact of
Ramakrishnan K; Kesavan R; Venkatraman S; Narayan SK; Kumar RR; Shewade D
Per Med; 2023 Sep; 20(5):417-424. PubMed ID: 37811569
[TBL] [Abstract][Full Text] [Related]
20. SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.
Shi L; Zhu M; Li H; Wen Z; Chen X; Luo J; Lin C; Zhang Z
Eur J Clin Pharmacol; 2019 May; 75(5):655-663. PubMed ID: 30693367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
